Allurion Technologies reports Q3 EPS ($1.53), consensus ($2.45)

Reports Q3 revenue $2.66M, consensus $2.05M. “In this past quarter at Allurion, we achieved several significant milestones toward FDA approval,” said Shantanu Gaur, founder and CEO of Allurion. “From July through October, we passed two FDA inspections with zero observations and successfully conducted our Day-100 meeting. We believe that we are now entering the final stages of the process.